| [1] | Baker L, Deal B (2004) Economic impact analysis: Proposition 71 California Stem Cell Research and Cures Initiative. New York: Analysis Group. Available: http://www.ag-inc.com/AnalysisGroup/uplo？adedFiles/News_and_Events/News/Propositi？on_71_report.pdf. Accessed 1 February 2006.
|
| [2] | California Council on Science and Technology [CCST] Intellectual Property Study Group (2005) Policy framework for intellectual property derived from stem cell research in California. Riverside (California): CCST. Interim report to the California legislature, governor of the state of California and the California Institute for Regenerative Medicine. Available: http://www.ccst.us/ccst/pubs/IP/IP%20Int？erim%20Exec.pdf. Accessed 1 February 2006.
|
| [3] | US Food and Drug Administration [FDA] (2005) Original INDs received calendar years 1986–2004. Rockville (Maryland): FDA. Available: http://www.fda.gov/cder/rdmt/Cyindrec.ht？m. Accessed 1 February 2006.
|
| [4] | Heller MA, Eisenberg RS (1998) Can patents deter innovation? The anticommons in biomedical research. Science 698–701.
|
| [5] | Eisenberg R (2001) Expanding the boundaries of intellectual property: Innovation policy for the knowledge society. In: Dreyfuss RC, editor. Bargaining over the transfer of proprietary research tools: Is this market failing or emerging? Oxford University Press. pp. 223–250.
|
| [6] | Wadman M (2005) Licensing fees slow advance of stem cells. Nature. E-pub 18 May 2005. Available: http://www.nature.com/news/2005/050516/p？f/435272a_pf.html. Accessed 1 February 2006.
|
| [7] | Geron1998 Nov 5. PNAS reports derivation of human pluripotent stem cells from cultured primordial germ cells. Menlo Park (California): Geron. Available: http://www.geron.com/pressview.asp?id=56？2. Accessed 1 February 2006.
|
| [8] | UK Stem Cell Initiative (2005) Report and recommendations. London: UK Department of Health. Available: http://www.advisorybodies.doh.gov.uk/uks？ci/uksci-reportnov05.pdf. Accessed 1 February 2006.
|
| [9] | Ebersole TJ, Edmond RW, Schwartzman RA (2005) Stem cells—Patent pools to the rescue? Washington (D. C.): Sterne Kessler Goldstein and Fox. Available: http://www.skgf.com/media/news/news.176.？PDF. Accessed 1 February 2006.
|
| [10] | Kesselheim AS, Avorn J (2005) University-based science and biotechnology products: Defining the boundaries of intellectual property. JAMA 850–854.
|
| [11] | Pollack A2005 Open-source practices for biotechnology. New York Times B: 1. 210
|
| [12] | Goozner M (2004) The $800 million pill: The truth behind the cost of new drugs. Berkeley: University of California Press. 296 p.
|
| [13] | US Congress (2005) Summary of the medical innovation prize fund, HR 417.109th Congress. 1st session (26 January 2005). Available: http://bernie.house.gov/documents/prescr？iptions/rd_read_the_bill.htm. Accessed 3 February 2006.
|
| [14] | Kesselheim A, Avorn J (2005) University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA 293: 850–854.
|
| [15] | Barton JH, Emanuel EJ (2005) The patents-based pharmaceutical development process: Rationale, problems and potential reforms. JAMA 294: 2075–2082.
|
